ALPHA CHYMOTRYPSIN

Indications

• Pancreatitis
• Surgical procedures requiring protein digestion
• Post-operative recovery
• Inflammatory conditions

Dosage

Children: Refer to established clinical guidelines for dosing recommendations.

Adults: Refer to established clinical guidelines for dosing recommendations.

Mechanism of action

Chymotrypsin functions by cleaving peptide bonds at the carboxyl side of aromatic amino acids, such as tryptophan, phenylalanine, and tyrosine. This proteolytic activity reduces the size of protein molecules, facilitating their absorption and utilization in the body. The enzyme's action is highly specific and efficient, contributing to the overall digestive process.

Pharmacodynamics

Chymotrypsin exhibits its effects primarily through its enzymatic activity, enhancing the digestion of dietary proteins and facilitating nutrient absorption. Additionally, it may exert anti-inflammatory effects by modulating the immune response and reducing edema in tissues. Its activity is influenced by factors such as pH, temperature, and the presence of other ions or molecules in the digestive system.

Pharmacokinetics

Chymotrypsin is administered orally or via injection, where it is absorbed through the gastrointestinal tract or directly into the bloodstream. Once in circulation, it is distributed to tissues where it exerts its enzymatic effects. The enzyme is subject to degradation by proteolytic enzymes in the body, and its activity can be influenced by the physiological state of the patient, including factors such as age, health status, and concurrent medications. The half-life of chymotrypsin varies based on the route of administration and individual patient factors.

Contra-indications

• Hypersensitivity to chymotrypsin or any component of the formulation
• Active bleeding disorders
• History of gastrointestinal ulcers
• Severe renal impairment

Adverse effects

• Allergic reactions including rash, itching, and anaphylaxis
• Gastrointestinal disturbances such as nausea, vomiting, and diarrhea
• Local irritation at the injection site
• Increased risk of bleeding due to its proteolytic activity

Interactions

• May enhance the effects of anticoagulants due to increased proteolytic activity
• Use with caution in patients taking other medications that affect hemostasis
• No significant drug-drug interactions are well documented

Precautions

• Use with caution in patients with a history of allergic reactions
• Monitor for signs of bleeding in patients with compromised hemostasis
• Assess renal function before administration in patients with renal impairment

Pregnancy

Chymotrypsin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, as studies on its safety in pregnant women are lacking.

Breast-feeding

It is not known whether chymotrypsin is excreted in human milk. Caution should be exercised when administering to nursing women.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Formulations

• Chymotrypsin injection solution
• Chymotrypsin enteric-coated tablets

Indications

• Nutritional supplementation
• Herbal therapy for various conditions
• Preservation of medicinal properties of plants

Dosage

Children: Dosage for dried herbal preparations in children should be approached cautiously and is best determined by a healthcare professional. Refer to paediatric guidelines for specific dosing recommendations.

Adults: Dosage for dried herbal preparations varies widely depending on the specific herb and its intended use. Refer to specific guidelines or reputable sources for dosing information.

Mechanism of action

The mechanism of action for dried herbal preparations varies depending on the specific plant material involved. Generally, the active constituents in dried herbs can exert their effects through various pathways, such as modulating neurotransmitter systems, influencing metabolic pathways, and acting on specific receptors in the body. For instance, flavonoids, terpenes, and alkaloids found in certain dried herbs can exhibit anti-inflammatory, antioxidant, or antimicrobial properties.

Pharmacodynamics

The pharmacodynamics of dried drugs depend on their specific chemical constituents. These compounds can affect physiological functions, such as modulating inflammatory responses, enhancing immune function, or affecting neurotransmission. The effects can vary widely based on the type of herb, the method of drying, and the concentration of active ingredients.

Pharmacokinetics

The pharmacokinetics of dried herbal preparations can vary significantly based on the specific herb used. Generally, after ingestion, the active compounds are absorbed in the gastrointestinal tract, metabolized primarily by the liver, and then excreted through urine or feces. The bioavailability of these compounds can be influenced by factors such as the form of the preparation (e.g., powder, extract), the presence of other food substances, and individual patient characteristics.

Pregnancy

Safety during pregnancy has not been established. Consult a healthcare provider before use.

Breast-feeding

Consult a healthcare provider before use during breastfeeding.

Storage

Store in a cool, dry place, away from direct sunlight.

Indications

• Local anesthesia of mucous membranes
• Topical anesthesia in oral and nasal procedures
• Laryngeal anesthesia

Dosage

Children: Refer to the BNF for Children for appropriate paediatric dosing, as it is based on age and weight.

Adults: Refer to the BNF for specific dosing guidance as it varies by indication and clinical scenario.

Mechanism of action

Cocaine produces anesthesia by reversibly binding to and inactivating sodium channels, which are essential for the depolarization and impulse propagation along nerve cells. Additionally, cocaine's blockade of norepinephrine reuptake leads to its vasoconstrictive effects. The drug also prevents the re-uptake of dopamine, serotonin, and norepinephrine into pre-synaptic neurons, influencing neurotransmitter levels.

Pharmacodynamics

Cocaine is primarily indicated for the introduction of local anesthesia in accessible mucous membranes, including those of the oral, laryngeal, and nasal cavities. Its rapid onset of action and potent local anesthetic properties make it effective for short procedures requiring localized pain relief.

Pharmacokinetics

Cocaine is absorbed quickly through mucous membranes and has a short duration of action. It undergoes extensive hepatic metabolism, primarily by enzymes such as CYP3A4 and CYP2D6, producing metabolites that are then excreted in urine. The onset of anesthesia typically occurs within minutes, while the effects can last from 30 minutes to several hours, depending on the route of administration and dosage.

Contra-indications

• Hypersensitivity to cocaine or any of its components
• Severe hypertension
• Severe coronary artery disease
• History of arrhythmias

Adverse effects

• Cardiovascular disturbances (e.g., hypertension, tachycardia)
• CNS effects (e.g., anxiety, agitation, seizures)
• Local tissue necrosis at the injection site
• Allergic reactions (e.g., rash, anaphylaxis)

Interactions

• Monoamine oxidase inhibitors (MAOIs) may enhance the effects of cocaine
• Other sympathomimetic drugs can increase cardiovascular effects
• Alcohol may potentiate the CNS effects of cocaine

Precautions

• Use with caution in patients with a history of substance abuse
• Monitor blood pressure and heart rate during administration
• Avoid use in patients with significant hepatic impairment
• Consider potential for addiction and abuse

Pregnancy

Cocaine is contraindicated during pregnancy due to potential harm to the fetus, including risk of miscarriage, premature birth, and developmental issues.

Breast-feeding

Cocaine is excreted in breast milk and may pose a risk to nursing infants; breastfeeding should be avoided during and after use.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Formulations

• Topical solution for mucous membrane application
• Injection solution for local anesthesia

Mechanism of action

Cocaine produces anesthesia by inhibiting excitation of nerve endings or by blocking conduction in peripheral nerves. This is achieved by reversibly binding to and inactivating sodium channels. Sodium influx through these channels is necessary for the depolarization of nerve cell membranes and subsequent propagation of impulses along the course of the nerve. Cocaine is the only local anesthetic with vasoconstrictive properties. This is a result of its blockade of norepinephrine reuptake in the autonomic nervous system. Cocaine binds differentially to the dopamine, serotonin, and norepinephrine transport proteins and directly prevents the re-uptake of dopamine, serotonin, and norepinephrine into pre-synaptic neurons. Its effect on dopamine levels is most responsible for the addictive property of cocaine. The presence and function of cannabinoid CB(2) receptors in the brain have been the subjects of much debate. /The investigators/ found that systemic, intranasal or intra-accumbens local administration of JWH133, a selective CB(2) receptor agonist, dose-dependently inhibited intravenous cocaine self-administration, cocaine-enhanced locomotion, and cocaine-enhanced accumbens extracellular dopamine in wild-type and CB(1) receptor knockout (CB(1)(-/-), also known as Cnr1(-/-)) mice, but not in CB(2)(-/-) (Cnr2(-/-)) mice. This inhibition was mimicked by GW405833, another CB(2) receptor agonist with a different chemical structure, and was blocked by AM630, a selective CB(2) receptor antagonist. Intra-accumbens administration of JWH133 alone dose-dependently decreased, whereas intra-accumbens administration of AM630 elevated, extracellular dopamine and locomotion in wild-type and CB(1)(-/-) mice, but not in CB(2)(-/-) mice. Intra-accumbens administration of AM630 also blocked the reduction in cocaine self-administration and extracellular dopamine produced by systemic administration of JWH133. These findings suggest that brain CB(2) receptors modulate cocaine's rewarding and locomotor-stimulating effects, likely by a dopamine-dependent mechanism. Cocaine hydrochloride is a local anesthetic which blocks initiation or conduction of nerve impulses following local application; when applied topically to mucous membranes, the drug also produces intense vasoconstriction. When applied topically to the mucous membranes of the nose or mouth, cocaine reduces the acuity of smell or taste, respectively. Cocaine exerts an indirect adrenergic effect by interfering with the uptake of norepinephrine by adrenergic nerve terminals, and therefore potentiates the effects of catecholamines. The indirect adrenergic effect is apparently the mechanism by which the drug produces vasoconstriction and mydriasis. Cocaine has CNS stimulating effects. The drug is also markedly pyrogenic, augmenting heat production by stimulating muscular activity and decreasing heat loss through vasoconstriction. Cocaine has multiple central and peripheral pharmacological actions. The action responsible for the rewarding property, and hence the abuse liability, of cocaine is an action in the dopaminergic synapse; in the rat the major set of critical dopaminergic synapses appears to be in the nucleus accumbens. Cocaine prolongs the activity of dopamine in the synapse by blocking the dopamine reuptake mechanism (which usually inactivates the transmitter by removing it from the proximity of its synaptic targets). This is an action shared with amphetamine; in addition to blocking the dopamine reuptake mechanism, amphetamine also augments dopaminergic function by augmenting dopamine release directly into the synapse. While amphetamine and cocaine have discriminable subjective effects, perhaps due to differences in rate of onset and metabolism or perhaps due to different side effects, cocaine shares its rewarding impact and abuse liability very closely with amphetamine. When drug access is unlimited, cocaine and amphetamine have the same ability to dominate behavior, reducing other beha

Pharmacodynamics

Cocaine is a local anesthetic indicated for the introduction of local (topical) anesthesia of accessible mucous membranes of the oral, laryngeal and nasal cavities.